Nellix 腔内动脉瘤封闭系统治疗腹主动脉瘤的两年结果
这项回顾性研究在3个高容量中心纳入355例连续接受第一代EVAS装置治疗的患者,其中264例择期无症状肾下型EVAS可分析;168例(63.3%)符合2013版IFU标准,其中48例(18.2%)符合修订版2016版IFU。研究显示,在IFU范围内使用EVAS的2年结果可接受,两版IFU之间无显著差异,但修订版IFU显著降低了该技术的适用性。
要点
- IFU 2013组总体技术成功率为98.2%(165/168),IFU 2016亚组为97.9%(47/48),p=0.428。
- 2年免于再干预率:IFU 2013组89.7%,IFU 2016亚组95.7%;前45例再干预显著更多(p=0.005)。
- IFU 2013组报告迁移≥10 mm或需干预的≥5 mm共12例(7.1%),IFU 2016亚组无。
核心结论
- 在IFU范围内使用EVAS的2年结果可接受,两版IFU之间无显著差异,但作者指出需要更长的随访。
- 修订版IFU显著降低了该技术的适用性。
研究设计与样本
- 回顾性研究,2013年4月至2015年12月31日在3个高容量中心连续纳入355例接受第一代EVAS装置治疗的患者。
- 355例中264例择期无症状肾下型EVAS适合分析;168例(63.3%)符合IFU 2013标准,其中48例(18.2%)符合修订版IFU 2016。
主要发现
- 总体技术成功率:IFU 2013组98.2%(165/168)vs IFU 2016亚组97.9%(47/48),p=0.428。
- 2年免于再干预率:IFU 2013组89.7% vs IFU 2016亚组95.7%;前45例再干预显著更多(p=0.005)。
- 狭窄/闭塞率:IFU 2013组6.5% vs IFU 2016亚组4.2%,p=0.705。
- IFU 2013组内漏9例(5.4%,8例Ia型、1例Ib型)vs IFU 2016亚组3例(2.1%),p=0.583。
- IFU 2013组迁移≥10 mm或需干预的≥5 mm共12例(7.1%),IFU 2016亚组无;IFU 2013组瘤体增长10例(6.0%),其中2例(4.2%)在IFU 2016亚组。
关键数值与推荐
- 2年总体生存率与免于动脉瘤相关死亡率:IFU 2013组分别为90.9%和97.6%,IFU 2016亚组分别为95.5%和100.0%。
- IFU 2016亚组并发症发生率似乎更低,但无显著差异。
临床怎么用
- 原文未据此给出推荐。
局限性
- 作者指出需要更长的随访。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: To analyze the 2-year outcomes of endovascular aneurysm sealing (EVAS) according to 2 versions of the instructions for use (IFU). METHODS: A retrospective study was conducted involving 355 consecutive patients treated with the first-generation EVAS device from April 2013 to December 31, 2015, at 3 high-volume centers. Out of 355 patients treated with EVAS, 264 were elective asymptomatic infrarenal EVAS procedures suitable for analysis. In this cohort, 168 (63.3%) patients were treated within the IFU 2013 criteria; of these 48 (18.2%) were in compliance with the revised IFU 2016 version. RESULTS: Overall technical success was 98.2% (165/168) in the IFU 2013 group and 97.9% (47/48) in the IFU 2016 subgroup (p=0.428). The 2-year freedom from reintervention estimates were 89.7% (IFU 2013) and 95.7% (IFU 2016), with significantly more reinterventions in the first 45 cases (p=0.005). The stenosis/occlusion estimates were 6.5% (IFU 2013) and 4.2% (IFU 2016; p=0.705). Nine (5.4%) endoleaks (8 type Ia and 1 type Ib) were observed within the IFU 2013 cohort; 3 (2.1%) were in the IFU 2016 subgroup (p=0.583). Migration ≥10 mm or ≥5 mm requiring intervention was reported in 12 (7.1%) patients in the IFU 2013 cohort but none within the IFU 2016 subgroup. Ten (6.0%) patients demonstrated aneurysm growth in the IFU 2013 cohort, of which 2 (4.2%) were in the IFU 2016 subgroup. Overall survival and freedom from aneurysm-related death estimates at 2 years were 90.9% and 97.6% in the IFU 2013 cohort (IFU 2016: 95.5% and 100.0%). The prevalence of complications seemed lower within IFU 2016 without significant differences. CONCLUSION: This study shows acceptable 2-year results of EVAS used within the IFU, without significant differences between the 2 IFU versions, though longer follow-up is indicated. The refined IFU significantly reduced the applicability of the technique.
引用
- Zoethout AC, Boersen JT, Heyligers JMM, et al. Two-Year Outcomes of the Nellix EndoVascular Aneurysm Sealing System for Treatment of Abdominal Aortic Aneurysms. J Endovasc Ther. 2018. PMID: 29591724. doi:10.1177/1526602818766864
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。